RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Autoimmunita' e intestino
• 2 - Modulazione dei meccanismi di apoptosi in corso di risposta immunitaria/infiammatoria: studio delle interazioni tra citochine della famiglia del TNF per la caratterizzazione di meccanismi molecolari e cellulari funzionali alla identificazione di nuovi target per la terapia di malattie croniche degenerative.
• 3 - Il sistema GITR/GITRL nelle malattie a patogenesi autoimmunitaria/infiammatoria: un bersaglio per la terapia farmacologica
• 4 - Il fenomeno della cross-presentazione ed i segnali immunomodulatori nella genesi di patologie infettive ed autoimmuni
• 5 - L'apoptosi nei processi immunitari ed infiammatori: caratterizzazione di meccanismi molecolari e cellulari finalizzata a interventi terapeutici innovativi.
• 6 - Nuove strategie immunomodulatorie nella Malattia di Graves: ruolo delle chemochine e delle cellule T regolatorie
• 7 - Vaccini contro i tumori Erbb2 positivi
• 8 - Rapporto ospite parassita nelle infezioni da clamidie e spirochete: immunità naturale e metabolismo lipidico studiati con tecniche convenzionali e con DNA microarray
• 9 - Meccanismi di danno della beta cellula e strategie di prevenzione della funzione beta cellulare nel diabete di tipo 1
• 10 - MALATTIE INFIAMMATORIE INTESTINALI DEL BAMBINO: STUDIO DELLA ESPRESSIONE DI GENI IN RAPPORTO ALLA IMMUNITA' INNATA, ALLA IMMUNITA' RITARDATA E ALLA RISPOSTA ALLA TERAPIA IMMUNOMODULANTE.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • MEDICINA INTERNA
  • ENDOCRINOLOGIA
• Area scientifico disciplinare: Scienze agrarie e veterinarie
  • MICROBIOLOGIA AGRARIA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Veneto

Bibliografia

1. Wells et al., (2003). Lactic acid bacteria as mucosal delivery vehicles. In: BJB Wood & PJ Warner (Eds), The genetic of lactic acid bacteria. Vol 3. (pp. 261-290). New York, USA: Kluwer Academic/ Plenum Publishers.
2. Blum et al., (2003). Intestinal microflora and homeostasis of the mucosal immune response: implications for probiotic bacteria. In: GW Tannock (Ed), Probiotics and prebiotics: where are we going?. (pp 311-329). Wymondham, UK: Caister Academic Press.
3. Mercenier A. (1999). Lactic acid bacteria as live vaccines. In: GW Tannock (Ed), Probiotics: a critical review? (pp 113-127). Wymondham, UK: Horizon Scientific Press.
4. Naidu et al., (1999). Probiotic spectra of lactic acid bacteria (LAB). Crit Rev Food Sci Nutr, 38:13-126.
5. Isolauri et al., (2001). Probiotics: effects on immunity. Am J Clin Nutr, 73(Suppl 2): 444-450.
6. Hols et al., (1997). Efficient secretion of the model antigen M6-gp41E in Lactobacillus plantarum NCIMB 8826. Microbiology, 143: 2733-2741.
7. Plant et al., (2002). Adjiuvant preperties and colonization potential of adhering and non-adhering Lactobacillus spp. Following oral administration to mice. FEMS Immunol Med Microb, 34: 105-111.
8. Grangette et al., (2001). Mucosal immune response and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect Immun. 69: 1547-1553.
9. Reveneau et al., (2002). Comparison of the immune responses induced by local immunizations with recombinant Lactobacillus plantarum producing tetanus toxin fragmant C in differnt cellular locations. Vaccine, 20: 1769-1777.
10. Maassen et al., (1999). Instruments for oral disease-intervention strategies: recombinant Lactobacillus casei expressing tetanus fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis. Vaccine, 17: 2117-2118.
11. Maassen et al., (2003). Reduced experimental autoimmune encephalomyelitis after intranasal and oral administration of recombinant lactobacilli expressing myelin antigens. Vaccine, 21: 4685-4693.
12. Lernmark Å, Falorni A. (1997). Immunology of insulin-dependent diabetes mellitus. In: Pickup J, Williams G (eds) Textbook of Diabetes, pp. 15.1-15.23. Blackwell Science Ltd.,.
13. Sanjeevi et al., (1996). Diab.Nutr.Metab. 9:167-182.
14. Falorni et al.(1995). Radioimmunoassay detects the frequent occurrence of autoantibodies to the Mr 65,000 isoform of glutamic acid decarboxylase in Japanese insulin-dependent diabetes. Autoimmunity 19:113-125.
15. Falorni et al., (1995). Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands. J. Immunol. Methods 186,89-99 (1995).
16. Vandewalle et al., (1995). High diagnostic sensitivity of glutamate decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years. The Belgian Diabetes Registry. J. Clin. Endocrinol. Metab. 80:846-851.
17. Vandewalle et al., (1997). Associations of GAD65- and IA-2-autoantibodies with genetic risk markers in new-onset IDDM patients and their siblings. Diabetes Care 10:1547-1552.
18. Falorni et al., (1998). Controversies on humoral immune markers of insulin-dependent diabetes mellitus. J Ped Endocrinol Metab 11:307-317.
19. Yoon et al., (1999). Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science 284: 1183-1187.
20. Yu L et al., (2000). Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci USA 97: 1701-1706.
21. Dubois-Laforgue et al., (1999). T-cell response to proinsulin and insulin in type 1 and pretype 1 diabetes. J Clin Immunol 19: 127-134.
22. Daniel et al., (1995). Epitope specificity,cytokine production profile and diabetogenic activity of insulin-specific T-cell clones isolated from NOD mice. Eur J Immunol 25: 1056-1062.
23. Makino et al., (1980). Breeding of a non-obese, diabetic strain of mice. Exp. Anim. 29(1): 1-13.
24. Miller et al., (1988). Both the lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J. Immunol. 140(1): 52-58.
25. Wang et al., (1988). Effect of cyclosporine on immunologically mediated diabetes in nonobese diabetic mice. Transplantation 46, Suppl.: 101S-106S.
26. Wang et al., (1990). The pathogenesis of immunologically mediated diabetes In Autoimmunity and The Pathogenesis of Diabetes. Ginsberg-Fellner F, McEvoy RC, Eds. New York, Springer-Verlag, p. 184-205.
27. Mosmann et al., (1986). Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136(7): 2348-2357, 1986.
28. Mosmann et al., (). TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann. Rev. Immunol. 7: 145-173.
29. Shehadeh et al., (1994). Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 343: 706-707.
30. Calcinaro et al., (). Protection from autoimmune diabetes by adjuvant therapy in the non-obese diabetic mouse: the role of interleukin-4 and interleukin-10. Immunol Cell Biol 75: 467-71,1997.
31. Weiner HL. Oral tolerance. Proc Natl Acad Sci USA 91: 10762-10765, 1994.
32. Weiner et al., (1993). Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259: 1321-1324.
33. Zhang et al., (1990). Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J Immunol 145: 2489-2493.
34. Nussenblatt et al., (1990). Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J Immunol 144: 791-798.
35. Berlin et al., (1993). 74/integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 74: 185-195.
36. Hänninen et al., (1996). Mucosa-associated (7-integrinhigh) lymphocytes accumulate early in the pancreasMucosa-associated ( of NOD mice and show aberrant recirculation behaviour. Diabetes 45: 1173-1180.
37. Tian et al., (1996). Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. 183: 1561-1567.
38. Zhang et al., (1991). Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 88: 10252-10256.
39. Hancock et al., (1996). Suppression of insulitis in Non-obese Diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-b, and prostaglandin-E. Am J Pathol 147: 1193-1199.
40. Muir et al., (1995). Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J Clin Invest 95: 628-634.
41. Daniel et al., (1996). Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 93: 956-960.
42. Rudy et al., (1995). Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T-cells of individuals at risk for insulin-dependent diabetes. Mol Med 1: 625-633.
43. Martinez et al., (2003). Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J Clin Invest 111: 1365-1371.
44. Chen et al., (1996). Dose-dependent activation and deletion of antigen-specific T cells following oral tolerance. Ann NY Acad Sci 778: 111-121.
45. Ma et al., (1997). Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nature Med 3: 793-796.
46. Arakawa et al., (1998). A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nature Biotech 16: 934-938.

Parole Chiave

DIABETE MELLITO TIPO 1; TOLLERANZA ORALE; GAD65; INSULINA; PROBIOTICI; LATTOBACILLI; TOPO NOD; PREVENTION